Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.46 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.40 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28871432 | 0.90 | PLA2G2A (0.44) | BRD4SERPINE1PTGES2PTGESPPARG | |
| SCHEMBL6690216 | 0.86 | PLA2G2A (0.43) | SERPINE1PPARGALDH1A1CCR2PGR | |
| SCHEMBL6776773 | 0.84 | PLA2G2A (0.42) | SERPINE1PTGES2PTGESPPARGALDH1A1 | |
| SCHEMBL28173636 | 0.84 | PLA2G2A (0.47) | BRD4SERPINE1PLA2G2AICMTPLA2G1B | |
| SCHEMBL6129599 | 0.84 | SERPINE1 (0.46) | BRD4SERPINE1ALDH1A1CCR2PLA2G2A | |
| SCHEMBL27508087 | 0.83 | ALDH1A1 (0.39) | SERPINE1PTGES2PPARGALDH1A1CCR2 | |
| SCHEMBL7753924 | 0.83 | SERPINE1 (0.47) | BRD4SERPINE1PTGES2PTGESALDH1A1 | |
| SCHEMBL2580436 | 0.81 | ALDH1A1 (0.55) | ALDH1A1CCR2ADRA1DPLA2G2APLA2G1B | |
| SCHEMBL6771677 | 0.81 | PLA2G2A (0.41) | PPARGALDH1A1CCR2PGRADRA1D | |
| SCHEMBL818733 | 0.80 | PLA2G2A (0.50) | PLA2G2APLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | PLA2G12A, PLA2G3, PLA2G1B | BRD4 169/4885SERPINE1 77/4885PTGES2 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.